Literature DB >> 15784302

Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.

H Fedorow1, F Tribl, G Halliday, M Gerlach, P Riederer, K L Double.   

Abstract

Neuromelanin (NM) is a dark polymer pigment produced in specific populations of catecholaminergic neurons in the brain. It appears in greatest quantities in the human brain, in lesser amounts in some other non-human primates, but is absent from the brain in many lower species. Interest in this pigment has seen a resurgence in recent years because of a hypothesised link between neuromelanin and the especial vulnerability of neuromelanin-containing neurons to cell death in Parkinson's disease (PD). Little is known regarding the biology of neuromelanin. As neuromelanin appears to have characteristics in common with the better studied peripheral melanin pigments this review compares what is known about neuromelanin with melanins found in other body tissues. Unlike peripheral melanins, which are produced in specialised cells called melanocytes and may be transferred to other cell types, neuromelanin granules are believed to be stored in the cell in which they are produced. Neuromelanin granules display a unique, more heterogeneous appearance compared with peripheral melanins. Unlike melanin, neuromelanin is traditionally thought to result from a non-enzymatic synthesis pathway with no known pathway for neuromelanin catabolism. More recent data, however, is indicative of some regulation of neuromelanin synthesis and turnover. By analogy with peripheral melanins, neuromelanin may function in vivo to attenuate the effects of damaging stimuli. Among several possible mechanisms suggested, the ability of neuromelanin to interact with transition metals, especially iron, and to mediate intracellular oxidative mechanisms has received particular attention. Recent data from neuromelanin in the Parkinson's disease brain suggests that this proposed function may be compromised, thus rendering pigmented neurons vulnerable to oxidative damage in this disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784302     DOI: 10.1016/j.pneurobio.2005.02.001

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  92 in total

Review 1.  Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.

Authors:  M Fasano; B Bergamasco; L Lopiano
Journal:  J Neural Transm (Vienna)       Date:  2006-05-12       Impact factor: 3.575

Review 2.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 3.  Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle.

Authors:  F Tribl; K Marcus; H E Meyer; G Bringmann; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

Review 4.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

5.  Encapsulation of a reactive core in neuromelanin.

Authors:  Shosuke Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

Review 6.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

7.  Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach.

Authors:  Florian Tribl; Esther Asan; Thomas Arzberger; Thomas Tatschner; Elmar Langenfeld; Helmut E Meyer; Gerhard Bringmann; Peter Riederer; Manfred Gerlach; Katrin Marcus
Journal:  Mol Cell Proteomics       Date:  2009-03-24       Impact factor: 5.911

8.  Intrastriatal transplantation of retinal pigment epithelial cells for the treatment of Parkinson disease: in vivo longitudinal molecular imaging with 18F-P3BZA PET/CT.

Authors:  Lihong Bu; Renfei Li; Hongguang Liu; Wei Feng; Xiaoxing Xiong; Heng Zhao; Douglas Vollrath; Baozhong Shen; Zhen Cheng
Journal:  Radiology       Date:  2014-04-20       Impact factor: 11.105

9.  Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Authors:  Edna Grünblatt; Josefine Ruder; Camelia Maria Monoranu; Peter Riederer; Moussa Bh Youdim; Silvia A Mandel
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

10.  3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.

Authors:  Kimihiro Ogisu; Kohsuke Kudo; Makoto Sasaki; Ken Sakushima; Ichiro Yabe; Hidenao Sasaki; Satoshi Terae; Mitsuhiro Nakanishi; Hiroki Shirato
Journal:  Neuroradiology       Date:  2013-03-23       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.